After Achieving 52-Week High, Is Neurocrine Biosciences, Inc. (NBIX)’s Near-Term Analysis Positive?

May 16, 2018 - By Bernice Betts

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Logo

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.35, from 1.66 in 2017Q3. It is negative, as 18 investors sold Neurocrine Biosciences, Inc. shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported.
Price T Rowe Inc Md holds 6.23M shares. Dekabank Deutsche Girozentrale accumulated 112,500 shares. Comerica Bancorp has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Sterling Mgmt Ltd Llc accumulated 0.01% or 16,308 shares. Wellington Management Llp holds 0.05% or 3.15 million shares. California Pub Employees Retirement System accumulated 192,135 shares. 116,057 were accumulated by State Board Of Administration Of Florida Retirement Systems. Jennison Assoc Ltd has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Bluecrest Cap Management Limited reported 17,176 shares or 0.04% of all its holdings. Voloridge Inv Mngmt Ltd Limited Liability Company invested in 140,756 shares. Shell Asset Mgmt stated it has 0.03% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). State Of Alaska Department Of Revenue, a Alaska-based fund reported 6,400 shares. 54,508 are owned by Dafna Mngmt Ltd Liability Company. Us State Bank De accumulated 398 shares or 0% of the stock. X Mngmt Lc holds 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 606 shares.

Since January 2, 2018, it had 0 insider purchases, and 24 insider sales for $40.25 million activity. GORMAN KEVIN CHARLES sold $8.50 million worth of stock or 105,983 shares. OBrien Christopher Flint had sold 2,613 shares worth $217,341 on Monday, February 5. Another trade for 5,000 shares valued at $415,625 was made by Nevinny Corinne H on Monday, May 7. Gano Kyle sold $128,460 worth of stock or 1,625 shares. RASTETTER WILLIAM H sold 9,500 shares worth $855,000. 960 shares were sold by Lloyd-Smith Malcolm, worth $79,863.

The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) hit a new 52-week high and has $100.31 target or 7.00 % above today’s $93.75 share price. The 8 months bullish chart indicates low risk for the $8.43 billion company. The 1-year high was reported on May, 16 by Barchart.com. If the $100.31 price target is reached, the company will be worth $589.96 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.89% or $0.83 during the last trading session, reaching $93.75. About 412,088 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since May 16, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on August, 2. They expect $-0.17 earnings per share, up 75.00 % or $0.51 from last year’s $-0.68 per share. After $-0.47 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -63.83 % EPS growth.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 10 analysts covering Neurocrine (NASDAQ:NBIX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine has $139.0 highest and $85.0 lowest target. $107’s average target is 14.13% above currents $93.75 stock price. Neurocrine had 20 analyst reports since December 12, 2017 according to SRatingsIntel. On Wednesday, February 14 the stock rating was maintained by JP Morgan with “Overweight”. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Wednesday, February 14 by Deutsche Bank. The firm earned “Buy” rating on Tuesday, May 1 by Deutsche Bank. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, February 14. The firm earned “Buy” rating on Thursday, February 22 by Oppenheimer. The firm earned “Buy” rating on Tuesday, May 1 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, December 12 by Oppenheimer. The stock has “Buy” rating by Piper Jaffray on Monday, January 8. The firm earned “Overweight” rating on Tuesday, May 1 by JP Morgan. On Wednesday, March 21 the stock rating was maintained by Oppenheimer with “Buy”.

More important recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Streetinsider.com which released: “UPDATE: Neurocrine Bio. (NBIX) PT Raised to $120 at Oppenheimer” on May 14, 2018, also Globenewswire.com published article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Fred’s, Nexstar Broadcasting Group, CNO Financial …”, Streetinsider.com published: “Baird KOL Panel Says Neurocrine Biosciences’ (NBIX) Opportunity Could Be Double Expectations” on May 16, 2018. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was released by: Fool.com and their article: “3 Top Biotech Stocks to Buy in May” with publication date: May 09, 2018.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $8.43 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.